LNLandry Nfonsam

Landry Nfonsam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Landry Nfonsam has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Characterization of a Novel, Recurrent 40.6 kb α 0 ‐Thalassemia Deletion in Canadians of East Indian Descent

    by John S. Waye, Meredith Hanna, Betty‐Ann Hohenadel, Lisa Nakamura, Lynda Walker, Landry E. Nfonsam, Heli Yadav, Barry Eng

    Introduction: Large α 0 ‐thalassemia deletions involving both HBA1 and HBA2 genes are rare in South Asian populations and remain under‐characterized. We describe a novel 40.6 kb α 0 ‐thalassemia deletion identified in multiple unrelated Canadians of East Indian descent and assess its molecular and clinical significance. Methods: Individuals with suspected α‐thalassemia trait were identified by complete blood count and hemoglobin analysis. Samples with microcytosis and/or hypochromia and normal Hb A 2 underwent molecular testing, including gap‐PCR for common deletions, Sanger sequencing, and multiplex ligation‐dependent probe amplification. Deletion breakpoints were defined by targeted PCR and Sanger sequencing. A specific gap‐PCR assay was developed for rapid detection, and retrospective screening was performed. Results: Twelve unrelated carriers of a 40.6 kb deletion removing HBZ , HBA2 , and HBA1 were identified. All showed hematologic features consistent with α‐thalassemia trait (MCV 65.4 ± 3.6 fL, MCH 20.2 ± 1.1 pg, normal Hb A 2 ). Breakpoint analysis demonstrated non‐homologous recombination between Alu elements. Recurrence among individuals of similar ancestry suggests a founder effect. We identified two couples at 25% risk for having children with Hb H disease due to compound heterozygosity for the 40.6 kb deletion and α + ‐thalassemia mutations, and diagnosed two Hb H disease patients with genotypes involving the 40.6 kb deletion. Conclusions: This novel α 0 ‐thalassemia deletion is a recurrent and likely under‐recognized cause of α‐thalassemia and Hb H disease in individuals of East Indian ancestry, underscoring the need for population‐specific molecular testing strategies.

  • Open Access

    ClinGen Hemoglobinopathy VCEP ACMG/AMP specifications for HBB and HBA2 variant interpretation in thalassemia

    by Coralea Stephanou, Irene Fylaktou, Hashim Halim-Fikri, Tamara T Koopmann, Landry E Nfonsam, Celeste Bento, Cornelis L Harteveld, Marina Kleanthous, Joanne Traeger-Synodinos, Kyriaki Michailidou, et al.

    Background: The ClinGen Hemoglobinopathy Variant Curation Expert Panel (VCEP) was established in 2019 to develop disease-specific adaptations of the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) sequence variant interpretation framework for hemoglobinopathies. This study describes the development, validation, and ClinGen approval of the first disease-specific ACMG/AMP specifications for autosomal recessive thalassemia related to HBB and HBA2, providing a standardized framework for globin gene variant interpretation. Methods: Disease-specific ACMG/AMP rule specifications were developed in accordance with ClinGen procedures and Variant Classification Working Group recommendations and evaluated through pilot curation of representative HBB and HBA2 variants using the ClinGen Variant Curation Interface (VCI), with independent biocurator assessment, expert review, and consensus approval. Results: A total of 34 disease-specific evidence specifications were developed across the two gene-disease pairs, encompassing 22 ACMG/AMP evidence criteria and one modification to the ACMG/AMP evidence-combining rules. Pilot application to 33 representative variants (20 HBB, 13 HBA2) demonstrated high concordance with established pathogenic and benign classifications while providing a standardized framework for resolving variants with conflicting or limited evidence. Following pilot validation, the specifications received ClinGen approval, and all curated variants with supporting evidence were disseminated through the ClinGen Evidence Repository (ERepo) and ClinVar. Conclusions: The ClinGen Hemoglobinopathy VCEP specifications provide the first ClinGen-approved disease-specific ACMG/AMP rule specifications for HBB and HBA2 variants related to thalassemia. These specifications establish a robust and transparent framework for harmonized globin variant interpretation and provide a foundation for sustained expert curation, continued refinement through emerging evidence, and expansion to additional hemoglobinopathy gene-disease pairs.

  • Open Access

    Adapting the ACMG/AMP variant classification framework: A perspective from the ClinGen Hemoglobinopathy Variant Curation Expert Panel

    by Petros Kountouris, Coralea Stephanou, Carsten W. Lederer, Joanne Traeger‐Synodinos, Celeste Bento, Cornelis L. Harteveld, Eirini Fylaktou, Tamara T. Koopmann, Hashim Halim‐Fikri, Kyriaki Michailidou, et al.

    Accurate and consistent interpretation of sequence variants is integral to the delivery of safe and reliable diagnostic genetic services. To standardize the interpretation process, in 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published a joint guideline based on a set of shared standards for the classification of variants in Mendelian diseases. The generality of these standards and their subjective interpretation between laboratories has prompted efforts to reduce discordance of variant classifications, with focus on the expert specification of the ACMG/AMP guidelines for individual genes or diseases. Herein, we describe our experience as a ClinGen Variant Curation Expert Panel (VCEP) to adapt the ACMG/AMP criteria for the classification of variants in three globin genes (HBB, HBA2, HBA1) related to recessively inherited hemoglobinopathies, including five evidence categories, as use cases demonstrating the process of specification and the underlying rationale.


  • Utility of incorporating clinical information in variant interpretation for the Fibrillin-1 gene

    by Leichelle Little, Grace Ediae, Landry Nfonsam, Mahdi Ghani, Julie Richer, Lucas Bronicki

  • Open Access

    ALU transposition induces familial hypertrophic cardiomyopathy

    by Landry Nfonsam, Lijia Huang, Nancy Carson, Jean McGowan‐Jordan, Melanie Beaulieu Bergeron, Sharan Goobie, Susan Conacher, David McCarty, Lee Benson, Stacy Hewson, et al.

    Background: Hypertrophic cardiomyopathy (HCM) is characterized by left ventricular hypertrophy (LVH) in the absence of predisposing cardiovascular conditions. Pathogenic variants in at least 16 cardiac sarcomeric genes have been implicated in HCM, most of which act in a dominant‐negative fashion. However loss‐of‐function (haploinsufficiency) is the most common disease mechanism for pathogenic variants in MYBPC3, suggesting that MYBPC3 complete deletion may play a role in HCM pathogenesis. Here, we investigate MYBPC3 complete deletion as a disease mechanism in HCM by analyzing two unrelated patients with confirmed diagnosis of HCM that tested negative by Sanger sequencing analysis.Methods: MYBPC3 complete deletion was investigated by Multiplex ligation‐dependent probe amplification (MLPA) and microarray analyses. The mechanism of deletion was investigated by interrogating the SINEBase database.Results: Patient‐1 was diagnosed with nonobstructive HCM in his mid‐40s while undergoing assessment for palpitations, and patient‐2 with obstructive HCM in his late‐20s while undergoing systolic heart murmur assessment for an unrelated illness. MLPA testing revealed a heterozygous deletion of all MYBPC3 exons in both patients. Subsequent microarray testing confirmed these deletions which extended beyond the 5′ and 3′ ends of MYBPC3. Genomic assessment suggested that these deletions resulted from Alu/Alu‐homologous recombination.Conclusion: Our results demonstrate that haploinsufficiency resulting from MYBPC3 complete deletion, potentially mediated by Alu recombination, is an important disease mechanism in cardiomyopathy and emphasizes the importance of copy number variation analysis in patients clinically suspected of HCM.


  • Genetic Diagnostic Testing for Inherited Cardiomyopathies

    by Hussein Daoud, Mahdi Ghani, Landry Nfonsam, Ryan Potter, Shelley Ordorica, Virginia Haslett, Nathaniel Santos, Heather Derksen, Donelda Lahey, Martha McGill, et al.


  • Leveraging the power of new molecular technologies in the clinical setting requires unprecedented awareness of limitations and drawbacks: experience of one diagnostic laboratory

    by Landry Nfonsam, Shelley Ordorica, Mahdi Ghani, Ryan Potter, Audrey Schaffer, Hussein Daoud, Nasim Vasli, Caitlin Chisholm, Elizabeth Sinclair-Bourque, Jean McGowan-Jordan, et al.

    Background: Advances in molecular technologies and in-silico variant prediction tools offer wide-ranging opportunities in diagnostic settings, yet they also present with significant limitations. Objective: Here, we contextualise the limitations of next-generation sequencing (NGS), multiplex ligation-dependent probe amplification (MLPA) and in-silico prediction tools routinely used by diagnostic laboratories by reviewing specific experiences from our diagnostic laboratory. Methods: We investigated discordant annotations and/or incorrect variant ‘callings’ in exons of 56 genes constituting our cardiomyopathy and connective tissue disorder NGS panels. Discordant variants and segmental duplications (SD) were queried using the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool and the University of California Santa Cruz genome browser, respectively, to identify regions of high homology. Discrepant variant analyses by in-silico models were re-evaluated using updated file entries. Results: We observed a 5% error rate in MYH7 variant ‘calling’ using MLPA, which resulted from >90% homology of the MYH7 probe-binding site to MYH6. SDs were detected in TTN, PKP2 and MYLK. SDs in MYLK presented the highest risk (15.7%) of incorrect variant ‘calling’. The inaccurate ‘callings’ and discrepant in-silico predictions were resolved following detailed investigation into the source of error. Conclusion: Recognising the limitations described here may help avoid incorrect diagnoses and leverage the power of new molecular technologies in diagnostic settings.